Monoclonal Antibody B43.13
Monoclonal Antibody B43.13 Uses, Dosage, Side Effects, Food Interaction and all others data.
Monoclonal Antibody B43.13 is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Monoclonal Antibody B43.13 is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.
| Trade Name | Monoclonal Antibody B43.13 |
| Generic | Oregovomab |
| Oregovomab Other Names | Monoclonal antibody B43.13, Oregovamab, Oregovomab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in ovarian cancer.
How Monoclonal Antibody B43.13 works
Monoclonal Antibody B43.13 targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.
Innovators Monograph
You find simplified version here Monoclonal Antibody B43.13
